Jose Karam

20PUBLICATIONS
114CO-AUTHORS
Toxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCatalysis and mechanisms of reactions
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 20, 2026
5x-Multiplier Versus 3-Tier Model: A Pragmatic Randomized Clinical Trial for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery.

|Aug 25, 2025
High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.

Yago Nieto, John F Ward, Wayne Hofstetter

|Jul 02, 2025
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Niki M Zacharias, Manuel Ozambela, Menuka Karki

|Jun 30, 2025
5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol.

Brittany C Fields, Timothy E Newhook, Heather A Lillemoe

|Feb 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.

Sangeeta Goswami, Jianjun Gao, Sreyashi Basu

|Jan 09, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.

Tejas Jammihal, Renee Maria Saliby, Chris Labaki

Pageof 4

Frequent Collaborators

6 joint publications

Matthew T Campbell

6 joint publications

Surena F Matin

4 joint publications

Christopher G Wood

3 joint publications

Sreyashi Basu